Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor
Postmortem brain examinations in Alzheimer’s disease (AD) reveal β-amyloid plaques, neurofibrillary tangles resulting from tau protein aggregation, and neuronal and synaptic loss, which collectively impair brain function. O-linked N-acetylglucosami-nidase (OGA) is an enzyme that removes O-linked β-N-acetylglucosamine (O-GlcNAc) from proteins including tau. In animal tauopathy models, OGA inhibition was shown to increase O-GlcNAc−tau levels, leading to reduced tau hyperphosphorylation and aggregation. These results inspired efforts to develop OGA inhibitors for the treatment of AD and tauopathies. Here we report the discovery and clinical development of ceperognastat (LY3372689), a low-dose, CNS-penetrant OGA inhibitor that has been evaluated in a completed phase II study in patients with early symptomatic AD.
Authors
- Feiyu Fred Zhang
- Hugh Norman Nuthall
- Susan L. DuBois
- Nicolas Dreyfus
- Peter J. Lindsay‐Scott (ORCID: https://orcid.org/0000-0002-4721-3594)
- Sergey Shcherbinin (ORCID: https://orcid.org/0009-0003-9451-1230)
- Jeremy Gilmore (ORCID: https://orcid.org/0000-0003-2551-5839)
- Jörg Hendle (ORCID: https://orcid.org/0000-0001-8857-0216)
- Eric M. Woerly (ORCID: https://orcid.org/0009-0000-2425-7597)
- David A. Price Evans (ORCID: https://orcid.org/0000-0002-8964-9169)
- William Kielbasa
- Dustin J. Mergott (ORCID: https://orcid.org/0000-0003-1802-0758)
- Kevin B. Donnelly (ORCID: https://orcid.org/0000-0002-1073-2593)
- Leonard L. Winneroski
- Michele Mancini (ORCID: https://orcid.org/0000-0002-1016-8443)
- Paul Goldsmith
- Richard E. Rathmell
- Emily C. Collins (ORCID: https://orcid.org/0009-0005-7065-7395)
- José Enrique López
- Stephen Loucian Lowe
- Adam S Fleisher
- Michael Hutton
Institutions
- Eli Lilly (United States) (US)
- Eli Lilly (United Kingdom) (GB)
- Eli Lilly (Singapore) (SG)
- Eli Lilly (Italy) (IT)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c02053
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00